Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of VYNE Therapeutics Inc. (NASDAQ:VYNE), it sends a favourable message to the company's shareholders.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

See our latest analysis for VYNE Therapeutics

The Last 12 Months Of Insider Transactions At VYNE Therapeutics

Over the last year, we can see that the biggest insider purchase was by Lead Independent Director Patrick LePore for US$51k worth of shares, at about US$3.91 per share. That means that even when the share price was higher than US$1.82 (the recent price), an insider wanted to purchase shares. Their view may have changed since then, but at least it shows they felt optimistic at the time. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.

In the last twelve months VYNE Therapeutics insiders were buying shares, but not selling. They paid about US$2.92 on average. I'd consider this a positive as it suggests insiders see value at around the current price. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

VYNE Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

VYNE Therapeutics Insiders Bought Stock Recently

It's good to see that VYNE Therapeutics insiders have made notable investments in the company's shares. Specifically, Lead Independent Director Patrick LePore bought US$51k worth of shares in that time, and we didn't record any sales whatsoever. This makes one think the business has some good points.

Does VYNE Therapeutics Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 6.9% of VYNE Therapeutics shares, worth about US$1.7m, according to our data. But they may have an indirect interest through a corporate structure that we haven't picked up on. We do generally prefer see higher levels of insider ownership.